Oncology PracticeNo increase in prostate cancer with testosterone therapyDecember 5, 2014Genitourinary Cancer
Oncology PracticeMen on androgen deprivation therapy not getting bisphosphonatesDecember 2, 2014Genitourinary Cancer
Hospital Physician: Hematology/OncologyMetastatic Prostate Cancer: A Case StudyDecember 1, 2014Genitourinary Cancer
Oncology PracticeFDA approves bevacizumab for ovarian cancer, with chemotherapyNovember 17, 2014Genitourinary CancerGynecologic Cancer
Oncology PracticeHas advertising for prostate cancer treatment gone too far?November 14, 2014Genitourinary Cancer
Oncology PracticeAndrogen-deprivation therapy linked to cardiac deathOctober 29, 2014Genitourinary Cancer
Oncology PracticeAdding abiraterone improves suppression of intraprostate androgensOctober 13, 2014Genitourinary Cancer
Oncology PracticeHypofractionation, vessel-sparing RT techniques for prostate cancer yield good QOLOctober 10, 2014Genitourinary Cancer
Oncology PracticeTrials close in on optimal ADT duration in high-risk prostate cancerSeptember 24, 2014Genitourinary Cancer
Oncology PracticeSpecific pattern of male baldness linked to aggressive prostate cancerSeptember 24, 2014Genitourinary Cancer
The Journal of Community and Supportive OncologyTreatment patterns and clinical effectiveness in metastatic castrate resistant prostate cancer after first-line docetaxelSeptember 23, 2014Genitourinary Cancer
Oncology PracticeBenefit from adjuvant RT for men with lymph node invasive prostate cancer varies with tumor characteristicsSeptember 22, 2014Genitourinary Cancer
Oncology PracticeFDA approves enzalutamide for chemo-naive metastatic prostate cancerSeptember 11, 2014Genitourinary Cancer
Oncology PracticeAndrogen deprivation should be continued indefinitely in men with metastatic castration-resistant prostate cancerSeptember 11, 2014Genitourinary Cancer
Oncology PracticeBlood marker may signal enzalutamide, abiraterone resistanceSeptember 3, 2014Genitourinary CancerBusiness of MedicinePractice Management
